, UK. All in vivo procedures were carried out in compliance with the United Kingdom Animal (Scientific Procedures) Act 1986 and associated Codes of Practice for the Housing and Care of Animals. Preparation of the HEC based RSV formulations has been described previously [13]. Briefly, a HiVac® Bowl (Summit Medical Ltd., Gloucestershire, UK) was used to facilitate mixing under vacuum following the stepwise

addition of components. Poylcarbophil (PC) (3% w/w) was first added to the bowl containing deionised water and sodium hydroxide prior to the addition of HEC (3 or 5% w/w) followed by polyvinylpyrollidone (PVP) (4% w/w). PC (3% w/w) was added to the vortex produced in a metal beaker by rapid stirring (at 500 rev min−1) of deionised water and the required amount of NaOH to reach pH 6 using a Heidolph mechanical stirrer. Following complete dissolution of the mucoadhesive component, NaCMC (3, 5 or 10% w/w) and PVP (4% w/w) were added stepwise following attainment of homogeneity. Volasertib The gels were transferred to sterile centrifuge tubes, gently centrifuged and stored for 24 h (ambient temperature) prior to analysis. Flow rheometry was conducted using an AR2000 rheometer (T.A. Instruments, Surrey, England) at 25 ± 0.1 °C using a 6 cm diameter 5-Fluoracil ic50 parallel plate geometry (selected according to formulation consistency) and a gap of 1000 μm, as previously reported [12]. Flow curves

(plots of viscosity versus shear rate) were examined in the range of 0.1–100 s−1. NaCMC semi-solid (2.8 g) was weighed into a 5 ml syringe barrel. The semi-solid loaded syringe barrel was attached to a second syringe via a 1.5 cm length of Nalgene tubing. CN54gp140 (200 μl at 530 μg/ml) was added to the semi-solid containing syringe barrel via pipette and the plunger replaced. Uniform distribution of CN54gp140 throughout the semi-solid formulation was achieved by carrying out 40 passes of the syringe barrel contents from one syringe to the other (method previously validated [13]). Semi-solids (HEC- and NaCMC-based) (0.36 g) were weighed into a speed mixing pot prior

to the addition of CN54gp140 (180 μl at 3.5 mg/ml). 2 Spin cycles at 3300 rpm for 30 s were carried out to provide uniform antigen distribution throughout the semi-solid until formulations. The same lyophilization protocol was adopted for each formulation. To optimise the lyophilization protocols, the glass transition temperatures of the selected and cooled semi-solid formulations were investigated by DSC using hermetic pans (DSC Q100, TA Instruments, Surrey, UK). Following cooling to −60 °C and holding isothermally for 5 min, the samples were heated at 2–40 °C using a modulated procedure (±0.4 °C every 0.5 s). Prior to lyophilization, semi-solid formulations were dispensed into suitable blister packs using a TS250 Digital Timed Dispenser (Adhesive Dispensing Ltd., Buckinghamshire, UK) for tablet formation or alternatively extruded into nalgene tubing with the use of a 5 ml syringe for rod formation.